Disclosure. Objectives. Osteoporosis. Major Public Health Concern Will I end up like my mother?

Size: px
Start display at page:

Download "Disclosure. Objectives. Osteoporosis. Major Public Health Concern Will I end up like my mother?"

Transcription

1 Everything a Pharmacist Needs to Know About Osteoporosis New Mexico Pharmacists Association Mid-Winter Meeting January 27-28, 2018 Albuquerque, NM Consulting Amgen, Radius Speaking Radius Disclosure E. Michael Lewiecki, MD, FACP, FACE Director, New Mexico Clinical Research & Osteoporosis Center Director, Bone Health TeleECHO University of New Mexico Health Sciences Center Albuquerque, NM Objectives Recognize osteoporosis treatment guidelines Define balance of benefits and risk with treatment Demonstrate risk communication techniques Osteoporosis A skeletal disorder characterized by compromised bone strength predisposing to an increased risk of fracture Bone strength reflects the integration of two main features: bone density and bone quality NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. March 27-29, Published in JAMA. 2001;285: Images by David Dempster, PhD. Major Public Health Concern Will I end up like my mother? Fracture Risk Assessment Intervention Thresholds 54 million Americans with osteoporosis or low BMD 2 million osteoporotic fractures each year Direct healthcare costs about $19 billion per year Increase is mortality, disability, loss of independence US Department of Health and Human Services. Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD: US Department of Health and Human Services, Office of the Surgeon General; National Osteoporosis Foundation. Accessed Treatment Follow-up 1

2 Normal WHO Classification of BMD T-score -1.0 or higher Osteopenia Between -1.0 and -2.5 Osteoporosis Severe Osteoporosis -2.5 or lower -2.5 or lower + fragility fracture Applies to postmenopausal women and men age 50 and older. Cannot be used in premenopausal women and men under age 50. Should never be used in children (under age 20). T-score -2.5 is not always osteoporosis. A patient may have osteoporosis with a T-score > WHO Study Group ISCD Official Positions. NOF Treatment Guidelines For postmenopausal women and men age 50 and older, after appropriate evaluation for secondary causes Osteoporosis by T-score T-score -2.5 or less at FN, TH, or LS, or... Clinical Osteoporosis Hip or vertebral (clinical or morphometric) fracture, or... Low BMD + High Fx Risk T-score between -1.0 and -2.5 at FN, TH, or LS, and... FRAX 10-year probability of hip fracture 3% or major osteoporotic fracture 20% National Osteoporosis Foundation. Clinician s Guide to Prevention and Treatment of Osteoporosis Medications for Osteoporosis Individualizing Initial Treatment Inhibit Bone Resorption (Antiresorptive) Alendronate (Fosamax, generic) Risedronate (Actonel, Atelvia, generic) Ibandronate (Boniva, generic) Zoledronate (Reclast, generic) Denosumab (Prolia) Raloxifene (Evista, generic) Salmon Calcitonin (Miacalcin, generic) Estrogen (various) CE/Baxedoxifene (Duavee) Stimulate Bone Formation (Anabolic) Teriparatide (Forteo) Abaloparatide (Tymlos) Agent Oral BPs ZOL Dmab TPT Abalo RLX Comments Pro: inexpensive, work well in many patients Con: GI distress, avoid with low GFR, bad rep in lay press Pro: very long dosing interval, post-hip fracture data Con: acute phase reaction, avoid with low GFR, IV Pro: long dosing interval, greatest BMD increase, SC Con: FDA list of side effects (back pain, high cholesterol, etc.) Pro: anabolic Con: high cost, daily injection, refrigeration, rat osteosarcoma Pro: anabolic, no refrigeration, less hypercalcemia than TPT Con: cost, daily injection, rat osteosarcoma Pro: not a BP, decreases breast cancer risk Con: VTE, hot flashes, no proven hip fracture decrease Personal opinion. Indications Medication PMO GIO (Women, Men) Men Prevention Treatment Prevention Treatment Estrogen (many forms) CE/BZA (Duavee) Raloxifene (Evista, generic) Alendronate (Fosamax, generic) Risedronate (Actonel, generic) Risedronate DR (Atelvia) Ibandronate PO (Boniva, generic) Ibandronate IV (Boniva) Zoledronate (Reclast, generic) Calcitonin IN (Miacalcin, generic) Denosumab (Prolia) Teriparatide (Forteo) Abalopartide (Tymlos) Fracture Risk Reduction in RCTs Medication Spine Nonvertebral Hip Estrogen (many forms) CEE/BZA (Duavee) / /- /- Raloxifene (Evista, generic)) - - Alendronate (Fosamax, generic) Risedronate (Actonel, generic) Ibandronate (Boniva, generic) ( in post hoc analyses) - Zoledronate (Reclast, generic) Calcitonin (Miacalcin, generic) - - Denosumab (Prolia) Teriparatide (Forteo) - Abaloparatide (Tymlos) - 2

3 Percent of Women Age 65+ A Brief History of Osteoporosis How did we get where we are today? E. Michael Lewiecki, MD Personal Opinion Better Worse Osteoporosis Care WHI (2002) FRAX Guidelines USA DXA Reimbursement Cuts (2007) ONJ Bureaucracy Limited Time AFF Media Reports Fear of Side Effects More Marketing Competing Priorities Drug Holidays Approval of More Drugs Competing Calcium US Surgeon General s Report Guidelines Vitamin D Increasing Availability of DXA Risk Communication Bone Mass Measurement Act Treatment Gap Mass Marketing Approval of Alendronate (1995) CRISIS WHO Diagnostic Criteria (1994) DXA Introduced (1987) Then Now Treatment Gap Getting Worse Review of US insurance claims data (commercial + Medicare) in 96,887 patients hospitalized with hip fracture, Reduced Bisphosphonate Prescription Rates Starting in 2008 Solomon DH et al. J Bone Miner Res. 2014;29: Jha S et al. J Bone Miner Res. 2015;30: % 24% 22% 20% 18% 16% 14% 12% 10% US Hip Fracture Trends $139 Hip Fracture Rates DXA Medicare Payments Osteoporosis Diagnosis DXA Testing $82 14,391 additional hip fractures $576 million additional expenses 2,878 additional deaths 13.2% 17.9% $ % % Fractures per 100,000 Women Age 65+ Age-adjusted to the 2014 Age Distribution Strategies to Reduce the Treatment Gap Public awareness / empowerment of patients Shared decision making Alignment of incentives More effective use of current treatments New drug development Harmonization of guidelines Fracture liaison services Better risk communication Restore DXA reimbursement Improve DXA quality Treat-to-target Sharing knowledge (Bone Health TeleECHO) Lewiecki EM et al. ASBMR Oral Presentation #

4 Can pharmacists help? Survey of 1,222 Community Pharmacists in Canada Screening for Osteoporosis Screening for Risk of Falls Believed should be involved 47% 50% Actually were involved 17% 19% Barriers to providing these services Lack of time: 79% Lack of clinical tools: 65% Lack of coordination with other healthcare professionals: 55% Laliberte M-C et al. Osteoporos Int. 2013;24: Systematic Review of Pharmacist Interventions for Osteoporosis Care 25 studies identified (3 RCTs) Interventions included patient counseling, education, QUS, and physician contact Results: interventions increased DXA testing and calcium intake in high risk patients Limitations: study bias, no study examined adherence to treatment, more and better designed studies are needed What You Can Do (If you have the interest, the time, and the resources) Identify patients who qualify for DXA testing Educate patients on long-term glucocorticoids on high risk of fracture Counsel on falls prevention, calcium, and vitamin D Distribute educational materials Inform on correct administration of oral BPs Advise fracture patients on risk of future fractures Communicate balance of benefits and risks Assess adherence to therapy Recognize the myths, understand the data, and appreciate the uncertainties in osteoporosis care Elias MN et al. Osteoporos Int. 2011;22: Controversies / Uncertainties Indications for DXA Evaluation DXA Indications Testing intervals Quality Reimbursement Fracture risk assessment Wise use of FRAX Other algorithms Secondary causes Best w/u for a patient Treatment Non-pharmacological Best exercise Calcium and CV disease Target vitamin D level Pharmacological Initial drug selection How long to treat Changing therapy Combining therapy Benefit vs. risk Women age 65 and men age 70 Younger postmenopausal women, perimenopausal women, and men age based on risk factor profile Adults with fragility fracture, disease or condition associated with low BMD or bone loss Extracted from NOF Clinician s Guide to Prevention and Treatment of Osteoporosis and ISCD Official Positions,

5 High Fracture Risk with Any Dose UK General Practice Research Database 244,235 oral glucocorticoid users compared to 244,235 controls Prednisone: < 2.5 mg/day mg/day 7.5 mg/day There is no safe dose of prednisone van Staa TP et al. J Bone Miner Res. 2000;15: From Osteoporosis Canada at From American Bone Health at From National Osteoporosis Foundation at Osteoporosis Wheel of Fear Atrial Fib Jaw Rot Calcium with or without vitamin D intake from food or supplements has no relationship (beneficial or harmful) to the risk for cardiovascular and cerebrovascular disease, mortality, or all-cause mortality in generally healthy adults at this time. Kopecky SL et al. Ann Intern Med. 2016;165(12): Joint Pain Muscles Ache Back Pain Fatal Stroke Blood Clots Brittle Bones Femur Snaps Heartburn 5

6 Incidence of AFF per 100,000 person-years Bisphosphonate Safety Issues Side Effects Short-term GI distress Acute phase reaction Hypocalcemia Renal toxicity Long-term Osteonecrosis of the jaw Atypical femur fractures Questionable Chronic musculo-skeletal pain Atrial fibrillation Esophageal cancer Impaired fracture healing Side Benefits Improved implant survival risk of breast cancer risk of endometrial cancer risk of colorectal cancer risk of stroke risk of gastric cancer risk of MI in RA patients risk of type 2 DM mortality Prieto-Alhambra D et al. Arthritis Rheum. 2014;66: Chlebowski RT et al. J Clin Oncol. 2010;28: Newcomb PA et al. J Clin Oncol. 2015;33: Dreyfuss JH. CA Cancer J Clin. 2010;60: Newcomb PA et al. Br J Cancer. 2010;102: Rennert G et al. J Clin Oncol. 2010;28: Vestergaard P et al. Calcif Tissue Int. 2011;88: Rennert G et al. J Clin Oncol. 2011;9: Kang JH et al. Osteoporos Int. 2012;23: Abrahamsen B et al. J Bone Miner Res. 2012;27: Center JR et al. J Clin Endocrinol Metab. 2011;96: Wolfe F et al. J Bone Miner Res. 2013;28: Konstantinos A et al. J Clin Endocrinol Metab. 2015;100: Sambrook PN et al. Osteoporos Int. 2011;22: Lee P et al. J Clin Endocrinol Metab. 2016;101: Denosumab Safety Message to patients: The most common side effects of Prolia include back pain, pain in the arms and legs, high cholesterol, muscle pain, and bladder infections. Adverse reactions in 2% of Patients with Osteoporosis and More Frequent Than with PBO Term Prolia (N=3886) PBO (N=3876) Back Pain 1347 (34.7%) 1340 (34.6%) Pain in extremity 453 (11.7%) 430 (11.1%) Hypercholesterolemia 280 (7.2%) 236 (6.1%) Myalgia 114 (2.9%) 94 (2.4%) Cystitis 228 (5.9%) 225 (5.8%) and package insert May Osteonecrosis of the Jaw Atypical Femur Fractures Atypical Femur Fracture Unadjusted and Age-adjusted Risk of AFF According to Duration of Bisphosphonate Therapy Ruggiero SL. J Oral Maxillofac Surg. 2004;62: Years of Bisphosphonate Exposure Risk of AFF increases with duration of BP therapy (1). Risk of AFF is low in proportion to fractures prevented by BP therapy (1). After BP withdrawal, risk of AFF rapidly decreases by 70% per year (2). 1. Dell RM et al. J Bone Miner Res. 2012;27: ; 2. Schilcher J et al. N Engl J Med. 2011;364: Year Probabilities 80 year-old woman with FN T-score = -3.3 Benefits and Risks Motor Vehicle Accidents Osteoporosis Includes 0.01% Atypical Femur Fracture Risk Includes 0.5% Atypical Femur Fracture Risk Wearing seat belts reduces the risk of serious crash-related injuries and deaths by about 50% Treatment with bisphosphonates reduces the risk of fractures by about 50% Untreated probability of major osteoporotic fracture calculated by FRAX. ONJ estimate is ~1/100,000 patienttreatment-years from ASBMR Task Force by Khosla S et al. J Bone Miner Res 2007;22: AFF estimate untreated is ~0.01/10,000 and treated is ~5/10,000 patient-years from Schilcher J et al. N Engl J Med. 2011;364: Risk estimates assume long-term bisphosphonate therapy resulting in 50% reduction in fracture risk. MVA and murder data from the CDC at Image copyright 2011 Lewiecki EM. Slide version. There are about 2.3 million adults treated in ERs each year for injuries from MVAs and about 2 million osteoporotic fractures each year. The risk of seat belt injuries and serious side effects from osteoporosis treatment is very small in proportion to the benefits. Data from multiple sources. 6

7 Myth: Osteoporosis Drugs Don t Work After 5 Years Reality: The evidence supports antifracture efficacy for as long as 10 years in appropriately selected patients Uncertainty RCTs with a placebo group are typically 3 years for osteoporosis drugs No data beyond 10 years Drug Holiday Elective temporary withholding of bisphosphonate after at least 3-5 years in appropriate patients NOT drug retirement NOT stopping treatment NOT for non-bisphosphonates Rationale: persistence of anti-fracture benefit while possibly reducing long-term risks Very little data, many opinions Periodic reevaluation of balance of benefits and risks Studies with other drugs for chronic diseases are often far shorter, and we typically don t know the long-term effects of any drugs for any disease Adapted from Whitaker M et al. N Engl J Med. 2012;366: Black DM et al. N Engl J Med. 2012;366: Bonnick SL. J Clin Densitom. 2011;14: Watts NB et al. J Clin Endocrinol Metab. 2010;95: Postmenopausal Women Treated with Oral BP 5 Years or IV BP 3 Years Low fracture risk: hip T-score > -2.5 and no hip, spine, or multiple osteoporotic fracture before or during therapy Consider drug holiday of 2-3 years High fracture risk: hip T-score -2.5 or hip, spine, or multiple osteoporotic fracture before or during therapy Consider continuing oral BP up to 10 years and IV BP up to 6 years Adler RA et al. J Bone Miner Res. 2016;31: Adler RA et al. J Bone Miner Res. 2016;31: Loss of Fracture Protection after Discontinuation of Denosumab No Holiday with Denosumab Systematic review of literature on discontinuing Dmab Return of fracture risk to baseline after discontinuation and possible increase in risk of multiple VFs Stopping Dmab should be followed by alternative treatment Tsourdi E et al. ECTS Position Statement. Bone Epub. 7

8 Sequencing with Anabolic Therapy Anabolic after potent BP (ALN) - delay or attenuation of anabolic effect Anabolic after Dmab - BMD decrease transient/sustained Anabolic after mild antiresorptive (ET, RIS) - expected onset of anabolic effect Antiresorptive after anabolic - essential Bone Health Bone Health USA Participants: 21 Months 263 registered, 221 attended at least once, attendees each week Bone Health Self-Efficacy Outcomes Measures Expert Very competent Bone Health ECHO learners with direct patient care responsibilities who attended more than 10 clinics (n=10) After ECHO* Competent Other countries Canada Mexico Chile Brazil Trinidad and Tobago Ireland UK Lewiecki EM et al. ASBMR Average Slight skills Vague skills No skills N/A Before ECHO Lewiecki EM et al. ASBMR *P = (very large effect size; Cohen and Sawilowsky) Summary Osteoporosis is a common disease with serious consequences due to fractures Despite availability of effective and safe medications to reduce fracture risk, there is a large treatment gap We can do better 8

A Brief History of Osteoporosis

A Brief History of Osteoporosis Challenges in the Treatment of Osteoporosis Disclosure Institutional Grant / Research Support Amgen Consulting Amgen, Radius, Shire, Alexion Speaking Shire, Alexion E. Michael Lewiecki, MD New Mexico Clinical

More information

TREATMENT OF OSTEOPOROSIS HOLIDAYS OR NO HOLIDAYS? Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO

TREATMENT OF OSTEOPOROSIS HOLIDAYS OR NO HOLIDAYS? Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO TREATMENT OF OSTEOPOROSIS HOLIDAYS OR NO HOLIDAYS? Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO DISCLOSURES Honoraria: Amgen, Merck, Shire Consulting : AbbVie, Amgen, Merck,

More information

Osteoporosis Agents Drug Class Prior Authorization Protocol

Osteoporosis Agents Drug Class Prior Authorization Protocol Osteoporosis Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of

More information

Osteoporosis: How to Manage Long- Term Use of Bisphosphonates AKA Now What? David E Feinstein, DO, CCD November 15 th, 2017

Osteoporosis: How to Manage Long- Term Use of Bisphosphonates AKA Now What? David E Feinstein, DO, CCD November 15 th, 2017 Osteoporosis: How to Manage Long- Term Use of Bisphosphonates AKA Now What? David E Feinstein, DO, CCD November 15 th, 2017 Introduction A fracture due to OP occurs every 3 seconds around the world. 1

More information

AACE/ACE Osteoporosis Treatment Decision Tool

AACE/ACE Osteoporosis Treatment Decision Tool AACE/ACE Osteoporosis Treatment Decision Tool What is Osteoporosis? OSTEOPOROSIS is defined as reduced bone strength leading to an increased risk of fracture. Osteoporosis, or porous bones, occurs when

More information

Controversies in Osteoporosis Management

Controversies in Osteoporosis Management Controversies in Osteoporosis Management 2018 Northwest Rheumatism Society Meeting Portland, OR April 28, 2018 Michael R. McClung, MD, FACP Director, Oregon Osteoporosis Center Portland, Oregon, USA Institute

More information

How long to treat? Disclosure. What is the real problem? Conclusions

How long to treat? Disclosure. What is the real problem? Conclusions Disclosure How long to treat? 11 th Annual Update on Osteoporosis and Skeletal Health Institutional Grant / Research Support Amgen, Eli Lilly, Merck Consulting / Speaking Amgen, Eli Lilly, Merck, Radius

More information

Osteoporosis Update. UNM Continuum of Care Project March 24, E. Michael Lewiecki, MD

Osteoporosis Update. UNM Continuum of Care Project March 24, E. Michael Lewiecki, MD Osteoporosis Update UNM Continuum of Care Project March 24, 2017 E. Michael Lewiecki, MD New Mexico Clinical Research & Osteoporosis Center University of New Mexico School of Medicine Albuquerque, NM Disclosure

More information

Chau Nguyen, D.O. Rheumatologist Clinical Assistant Professor of Internal Medicine at Western University of Health Sciences

Chau Nguyen, D.O. Rheumatologist Clinical Assistant Professor of Internal Medicine at Western University of Health Sciences Chau Nguyen, D.O Rheumatologist Clinical Assistant Professor of Internal Medicine at Western University of Health Sciences I do not have any relationship with the manufacturer of any commercial products

More information

Osteoporosis: An Overview. Carolyn J. Crandall, MD, MS

Osteoporosis: An Overview. Carolyn J. Crandall, MD, MS Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA Objectives Review osteoporosis

More information

OSTEOPOROSIS IN MEN. Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO

OSTEOPOROSIS IN MEN. Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO OSTEOPOROSIS IN MEN Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO DISCLOSURES Speakers Bureau: Amgen, Radius Consultant: Abbvie, Amgen, Janssen, Radius, Sanofi Watts NB et

More information

Current Issues in Osteoporosis

Current Issues in Osteoporosis Current Issues in Osteoporosis California AACE 18TH Annual Meeting & Symposium Marina del Rey, CA September 15, 2018 Michael R. McClung, MD, FACP,FACE Director, Oregon Osteoporosis Center Portland, Oregon,

More information

9/9/2015 OSTEOPOROSIS WHAT S NEW AND ON THE HORIZON IN SCREENING, DRUG HOLIDAYS, SUPPLEMENTS, CONSERVATIVE THERAPY DISCLOSURES

9/9/2015 OSTEOPOROSIS WHAT S NEW AND ON THE HORIZON IN SCREENING, DRUG HOLIDAYS, SUPPLEMENTS, CONSERVATIVE THERAPY DISCLOSURES OSTEOPOROSIS WHAT S NEW AND ON THE HORIZON IN SCREENING, DRUG HOLIDAYS, SUPPLEMENTS, CONSERVATIVE THERAPY Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO DISCLOSURES Stock options/holdings,

More information

Updated Guidelines from NOF, NBHA, ISCD, IOF

Updated Guidelines from NOF, NBHA, ISCD, IOF Updated Guidelines from NOF, NBHA, ISCD, IOF October 11-12, 2018 E. Michael Lewiecki, MD, FACP, FACE Director, New Mexico Clinical Research & Osteoporosis Center Director, Bone Health TeleECHO University

More information

Learning Objectives. Controversies in Osteoporosis Prevention and Management. Etiology. Presenter Disclosure Information. Epidemiology.

Learning Objectives. Controversies in Osteoporosis Prevention and Management. Etiology. Presenter Disclosure Information. Epidemiology. 12:45 1:30pm Controversies in Osteoporosis Prevention and Management SPEAKER Carolyn Crandall, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Carolyn

More information

Page 1. Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018? What s New in Osteoporosis

Page 1. Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018? What s New in Osteoporosis Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018? Douglas C. Bauer, MD Professor of Medicine and Epidemiology & Biostatistics University of California, San Francisco What s

More information

2017 Santa Fe Bone Symposium McClung

2017 Santa Fe Bone Symposium McClung 217 Santa Fe Bone Symposium Insights into the Use of Anti-remodeling and Anabolic Agents for Osteoporosis Developing a Long-term Management Plan Michael R., MD, FACP Oregon Osteoporosis Center Portland,

More information

Diagnosis and Treatment of Osteoporosis: What s New and Controversial in ? What s New in Osteoporosis

Diagnosis and Treatment of Osteoporosis: What s New and Controversial in ? What s New in Osteoporosis Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018-19? What s New in Osteoporosis The crisis in treatment and compliance Douglas C. Bauer, MD Professor of Medicine and Epidemiology

More information

Osteoporosis Management

Osteoporosis Management Osteoporosis Management Lisa Voss PA C, CCD Laura Frontiero NP C, CCD Kaiser Healthy Bones Program San Diego Disclosures: Nothing to disclose www.zazzle.com 1 Overview How to diagnose Osteoporosis FRAX

More information

Long-term Osteoporosis Therapy What To Do After 5 Years?

Long-term Osteoporosis Therapy What To Do After 5 Years? Long-term Osteoporosis Therapy What To Do After 5 Years? Developing a Long-term Management Plan North American Menopause Society Philadelphia, PA October 11, 2017 Michael R. McClung, MD, FACP Institute

More information

Task Force Co-Chairs. Members

Task Force Co-Chairs. Members Managing Osteoporosis Patients After Long-Term Bisphosphonate Treatment Report of a Task Force* of the American Society for Bone and Mineral Research Robert A. Adler, MD Task Force Co-Chairs Ghada El-Hajj

More information

Calcium, Vitamin D and Bisphosphonates: Disclosures. Benefits, Risks and Drug Holiday. Calcium YES or NO? Calcium Bad News!!

Calcium, Vitamin D and Bisphosphonates: Disclosures. Benefits, Risks and Drug Holiday. Calcium YES or NO? Calcium Bad News!! Calcium, Vitamin D and Bisphosphonates: Benefits, Risks and Drug Holiday Disclosures I am disclosing financial relationships as follows: Global Advisory Boards: Amgen, Lilly, Merck, Novartis Research grants:

More information

Download slides:

Download slides: Download slides: https://www.tinyurl.com/m67zcnn https://tinyurl.com/kazchbn OSTEOPOROSIS REVIEW AND UPDATE Boca Raton Regional Hospital Internal Medicine Conference 2017 Benjamin Wang, M.D., FRCPC Division

More information

CASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS

CASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS 4:30-5:15pm Ask the Expert: Osteoporosis SPEAKERS Silvina Levis, MD OSTEOPOROSIS - FACTS 1:3 older women and 1:5 older men will have a fragility fracture after age 50 After 3 years of treatment, depending

More information

Osteoporosis Treatment Overview. Colton Larson RFUMS October 26, 2018

Osteoporosis Treatment Overview. Colton Larson RFUMS October 26, 2018 Osteoporosis Treatment Overview Colton Larson RFUMS October 26, 2018 Burden of Disease Most common bone disease 9.9 million Americans + 43.1 million Americans have low bone mineral density (BMD) Stealthy

More information

Osteoporosis: A Tale of 3 Task Forces!

Osteoporosis: A Tale of 3 Task Forces! Osteoporosis: A Tale of 3 Task Forces! Robert A. Adler, MD McGuire Veterans Affairs Medical Center Virginia Commonwealth University Richmond, Virginia, USA Disclosures The opinions are those of the speaker

More information

Page 1. Updates in Osteoporosis. I have no conflicts of interest. What is osteoporosis? What s New in Osteoporosis

Page 1. Updates in Osteoporosis. I have no conflicts of interest. What is osteoporosis? What s New in Osteoporosis Updates in Osteoporosis Jeffrey A. Tice, MD Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in Osteoporosis

More information

Update on Osteoporosis 2016

Update on Osteoporosis 2016 WELCOME! Update on Osteoporosis 2016 Jennifer J. Kelly, D.O., F.A.C.E. Associate Professor of Medicine Division of Endocrinology, Diabetes and Metabolism Upstate Medical University Director of the Clinical

More information

Learning Objectives. Controversies in Osteoporosis Prevention and Management. Definition. Presenter Disclosure Information.

Learning Objectives. Controversies in Osteoporosis Prevention and Management. Definition. Presenter Disclosure Information. 4 4:45 pm Controversies in Osteoporosis Prevention and Management SPEAKER Carolyn Crandall, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Carolyn

More information

Disclosures. Diagnostic Challenges in Osteoporosis: Whom To Treat 9/25/2014

Disclosures. Diagnostic Challenges in Osteoporosis: Whom To Treat 9/25/2014 Disclosures Diagnostic Challenges in Osteoporosis: Whom To Treat Ethel S. Siris, MD Columbia University Medical Center New York, NY Consultant on scientific issues for: AgNovos Amgen Eli Lilly Merck Novartis

More information

Treatments for Osteoporosis Expected Benefits, Potential Harms and Drug Holidays. Suzanne Morin MD FRCP FACP McGill University May 2014

Treatments for Osteoporosis Expected Benefits, Potential Harms and Drug Holidays. Suzanne Morin MD FRCP FACP McGill University May 2014 Treatments for Osteoporosis Expected Benefits, Potential Harms and Drug Holidays Suzanne Morin MD FRCP FACP McGill University May 2014 Learning Objectives Overview of osteoporosis management Outline efficacy

More information

What is Osteoporosis?

What is Osteoporosis? What is Osteoporosis? 2000 NIH Definition A skeletal disorder characterized by compromised bone strength predisposing a person to an increased risk of fracture. Bone strength reflects the integration of

More information

TREATING OSTEOPOROSIS IN 2018: WHAT'S OLD, WHAT'S NEW, WHAT'S UNPROVEN AND WHAT'S TRUE. Nelson B. Watts, MD

TREATING OSTEOPOROSIS IN 2018: WHAT'S OLD, WHAT'S NEW, WHAT'S UNPROVEN AND WHAT'S TRUE. Nelson B. Watts, MD TREATING OSTEOPOROSIS IN 2018: WHAT'S OLD, WHAT'S NEW, WHAT'S UNPROVEN AND WHAT'S TRUE Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO Honoraria: Amgen, Radius, Shire Consulting

More information

ACP Colorado-Evidence Based Management of Osteoporosis

ACP Colorado-Evidence Based Management of Osteoporosis ACP Colorado-Evidence Based Management of Osteoporosis Micol S. Rothman, MD Associate Professor of Medicine and Radiology Clinical Director Metabolic Bone Program University of Colorado School of Medicine

More information

Bone Health Update Susan L. Greenspan, MD Professor of Medicine University of Pittsburgh

Bone Health Update Susan L. Greenspan, MD Professor of Medicine University of Pittsburgh Bone Health Update 2018 Susan L. Greenspan, MD Professor of Medicine University of Pittsburgh The Problem 50% women and 20% of men have an osteoporotic fracture after age 50 2 million fractures annually

More information

John J. Wolf, DO Family Medicine

John J. Wolf, DO Family Medicine John J. Wolf, DO Family Medicine Objectives: 1. Review incidence & Risk of Osteoporosis 2.Review indications for testing 3.Review current pharmacologic & Non pharmacologic Tx options 4.Understand & Utilize

More information

Pharmacy Management Drug Policy

Pharmacy Management Drug Policy SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 9/29/2017 If the member s subscriber contract excludes coverage

More information

Osteoporosis and Lupus. Andrew Ruthberg, MD University Rheumatologists

Osteoporosis and Lupus. Andrew Ruthberg, MD University Rheumatologists Osteoporosis and Lupus Andrew Ruthberg, MD University Rheumatologists 1 Forget the medical terminology (osteoporosis, osteopenia, low bone mass, DEXA, DXA, T score etc) The bottom line is that you don

More information

Hot Topics in Osteoporosis and Fracture Prevention

Hot Topics in Osteoporosis and Fracture Prevention Hot Topics in Osteoporosis and Fracture Prevention Sid Feldman, MD CCFP (COE) FCFP Sandra Kim, MD, FRCPC November 15, 2018 Family Medicine Forum, Toronto Faculty/Presenter Disclosure Faculty: Sid Feldman

More information

Osteoporosis: Are your bones at risk of fracturing? Rachel Wallwork, MD Internal medicine resident Massachusetts General Hospital

Osteoporosis: Are your bones at risk of fracturing? Rachel Wallwork, MD Internal medicine resident Massachusetts General Hospital Osteoporosis: Are your bones at risk of fracturing? Rachel Wallwork, MD Internal medicine resident Massachusetts General Hospital What is Osteoporosis? Osteoporosis causes bones to lose density, become

More information

Pharmacy Management Drug Policy

Pharmacy Management Drug Policy SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide), Boniva injection (Ibandronate) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 10/15/2018 If the member s

More information

Updates in Osteoporosis. I have no conflicts of interest. What Would You Do? Mrs. C. What s New in Osteoporosis. Page 1

Updates in Osteoporosis. I have no conflicts of interest. What Would You Do? Mrs. C. What s New in Osteoporosis. Page 1 Updates in Osteoporosis Jeffrey A. Tice, MD Associate Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in

More information

Current and Emerging Strategies for Osteoporosis

Current and Emerging Strategies for Osteoporosis Current and Emerging Strategies for Osteoporosis I have nothing to disclose. Anne Schafer, MD Assistant Professor of Medicine Division of Endocrinology & Metabolism December 12, 2014 Outline Osteoporosis

More information

Advanced medicine conference. Monday 20 Tuesday 21 June 2016

Advanced medicine conference. Monday 20 Tuesday 21 June 2016 Advanced medicine conference Monday 20 Tuesday 21 June 2016 Osteoporosis: recent advances in risk assessment and management Juliet Compston Emeritus Professor of Bone Medicine Cambridge Biomedical Campus

More information

Osteoporosis/Fracture Prevention

Osteoporosis/Fracture Prevention Osteoporosis/Fracture Prevention NATIONAL GUIDELINE SUMMARY This guideline was developed using an evidence-based methodology by the KP National Osteoporosis/Fracture Prevention Guideline Development Team

More information

Updates in Osteoporosis

Updates in Osteoporosis Updates in Osteoporosis Jeffrey A. Tice, MD Associate Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in

More information

Parathyroid Hormone Analog for Osteoporosis Prior Authorization with Quantity Limit Criteria Program Summary

Parathyroid Hormone Analog for Osteoporosis Prior Authorization with Quantity Limit Criteria Program Summary Parathyroid Hormone Analog for Osteoporosis Prior Authorization with Quantity Limit Criteria Program Summary This prior authorization program applies to Commercial, NetResults A series, NetResults F series

More information

NEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT

NEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT NEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF OSTEOPOROSIS: OVERVIEW Definitions Risk factors

More information

Rheumatology. keeping Joints in Motion. Treating and Preventing Fractures

Rheumatology. keeping Joints in Motion. Treating and Preventing Fractures Rheumatology keeping Joints in Motion Treating and Preventing Fractures Robin K. Dore, MD Clinical Professor of Medicine David Geffen School of Medicine at UCLA, Los Angeles CA Private practice, Tustin

More information

AN OVERVIEW of TREATMENT: WHO and WHEN to TREAT

AN OVERVIEW of TREATMENT: WHO and WHEN to TREAT AN OVERVIEW of TREATMENT: WHO and WHEN to TREAT Dolores Shoback, MD Professor of Medicine, UCSF San Francisco VA Medical Center July 16, 21 ~ QUESTIONS ~ Who should receive therapy to prevent fractures?

More information

The Bare Bones of Osteoporosis. Wendy Rosenthal, PharmD

The Bare Bones of Osteoporosis. Wendy Rosenthal, PharmD The Bare Bones of Osteoporosis Wendy Rosenthal, PharmD Definition A systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase

More information

Bisphosphonates. Making intelligent drug choices

Bisphosphonates. Making intelligent drug choices Making intelligent drug choices Bisphosphonates are a first choice for treating osteoporosis, according to Kedrin E. Van Steenwyk, DO, an obstetrician/gynecologist at Sycamore Women s Center, Miamisburg,

More information

Reducing the Risk of Fracture in Postmenopausal Women: Guidance for Family Physicians. Please complete the preassessment before the session starts.

Reducing the Risk of Fracture in Postmenopausal Women: Guidance for Family Physicians. Please complete the preassessment before the session starts. Reducing the Risk of Fracture in Postmenopausal Women: Guidance for Family Physicians Please complete the preassessment before the session starts. Sponsorship and Support This educational activity is jointly

More information

Tipping the Balance: Strategies for Enhanced Detection and Treatment of Osteoporosis in Primary Care

Tipping the Balance: Strategies for Enhanced Detection and Treatment of Osteoporosis in Primary Care Tipping the Balance: Strategies for Enhanced Detection and Treatment of Osteoporosis in Primary Care February 7, 2013 Fort Lauderdale, Florida Educational Partner: Session 5: Tipping the Balance: Strategies

More information

How to treat osteoporosis With what and for how long?

How to treat osteoporosis With what and for how long? How to treat osteoporosis With what and for how long? Professor Neil Gittoes Consultant Endocrinologist & Honorary Professor Where will we be going? Drug therapies Current Indications Contraindications/unmet

More information

A Review of Bone Health Issues in Oncology

A Review of Bone Health Issues in Oncology A Review of Bone Health Issues in Oncology David L. Kendler MD FRCPC CCD Professor of Medicine (Endocrinology) University of British Columbia Vancouver Canada Disclosures David Kendler has received research

More information

Kristen M. Nebel, DO PENN/ LGHP Geriatrics. Temple Family Medicine Review

Kristen M. Nebel, DO PENN/ LGHP Geriatrics. Temple Family Medicine Review Kristen M. Nebel, DO PENN/ LGHP Geriatrics 10/3/17 Temple Family Medicine Review OBJECTIVES Define Revised 2017 American College of Physician Recommendations Screening, Prevention and Treatment Application

More information

Bone Health for Women: Current Research, Initiatives and Recommendations

Bone Health for Women: Current Research, Initiatives and Recommendations Page 1 BONE HEALTH FOR WOMEN: CURRENT RESEARCH, INITIATIVES AND RECOMMENDATIONS Dr. Melissa Kagarise This program has been brought to you by PharmCon PharmCon is accredited by the Accreditation Council

More information

Osteoporosis. Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective. Old Definition of Osteoporosis

Osteoporosis. Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective. Old Definition of Osteoporosis Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective Dr Dicky T.K. Choy Physician Jockey Club Centre for Osteoporosis Care and Control, CUHK Osteoporosis Global public health

More information

Osteoporosis: A Tale of 3 Task Forces!

Osteoporosis: A Tale of 3 Task Forces! Osteoporosis: A Tale of 3 Task Forces! Robert A. Adler, MD McGuire Veterans Affairs Medical Center Virginia Commonwealth University Richmond, Virginia, USA Disclosures The opinions are those of the speaker

More information

Page 1. New Developments in Osteoporosis. What s New in Osteoporosis

Page 1. New Developments in Osteoporosis. What s New in Osteoporosis New Developments in Osteoporosis Eliseo J. Pérez-Stable MD Professor of Medicine Division of General Internal Medicine Department of Medicine July 4, 2013 Declaration of full disclosure: No conflict of

More information

Fracture=Bone Attack:

Fracture=Bone Attack: Fracture=Bone Attack: Linking Hip Fractures to Osteoporosis Care Angela M. Cheung, MD, PhD, FRCPC Professor of Medicine, University of Toronto Potential Conflicts of Interests Industry Grants (to UHN)

More information

New Therapeutic Directions: Osteoanabolic and Antiresorptive Therapy in Combination Therapy and in Sequence

New Therapeutic Directions: Osteoanabolic and Antiresorptive Therapy in Combination Therapy and in Sequence New Therapeutic Directions: Osteoanabolic and Antiresorptive Therapy in Combination Therapy and in Sequence John P. Bilezikian, MD, PhD(hon), MACE Silberberg Professor of Medicine Vice-Chair for International

More information

Page 1. Current and Emerging Strategies for Osteoporosis. Osteoporosis Warm-Up: Which of the Following is True?

Page 1. Current and Emerging Strategies for Osteoporosis. Osteoporosis Warm-Up: Which of the Following is True? Current and Emerging Strategies for Osteoporosis Douglas C. Bauer, MD Professor of Medicine and Epidemiology & Biostatistics University of California, San Francisco No Disclosures Osteoporosis Warm-Up:

More information

New Developments in Osteoporosis: Screening, Prevention and Treatment

New Developments in Osteoporosis: Screening, Prevention and Treatment Osteoporosis: Overview New Developments in Osteoporosis: Screening, Prevention and Treatment Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Risk factors

More information

Therapeutic Updates in the Prevention and Treatment of Osteoporosis

Therapeutic Updates in the Prevention and Treatment of Osteoporosis Therapeutic Updates in the Prevention and Treatment of Osteoporosis 2013 Fall Managed Care Forum Las Vegas November 15, 2013 Steven T Harris MD FACP Clinical Professor of Medicine University of California,

More information

OSTEOPOROSIS: PREVENTION AND MANAGEMENT

OSTEOPOROSIS: PREVENTION AND MANAGEMENT OSTEOPOROSIS: OVERVIEW OSTEOPOROSIS: PREVENTION AND MANAGEMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Key Risk factors Screening and Monitoring

More information

Pharmacy Management Drug Policy

Pharmacy Management Drug Policy Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature generally recognized by the medical community. Guidelines

More information

Osteoporosis for the PCP and consultant COPYRIGHT. Harold Rosen, MD Director- Osteoporosis Prevention and Treatment Center

Osteoporosis for the PCP and consultant COPYRIGHT. Harold Rosen, MD Director- Osteoporosis Prevention and Treatment Center Osteoporosis for the PCP and consultant Harold Rosen, MD Director- Osteoporosis Prevention and Treatment Center Beth Israel Deaconess Medical Center Potential conflicts of interest None GOALS When to screen/treat?

More information

AACE. Osteoporosis Treatment: Then and Now

AACE. Osteoporosis Treatment: Then and Now AACE 25 th Annual Scientific and Clinical Congress Osteoporosis Treatment: Then and Now Orlando, FL May 28, 2016 Michael R. McClung, MD Oregon Osteoporosis Center Portland, Oregon, USA Disclosures I am

More information

An Update on Osteoporosis Treatments

An Update on Osteoporosis Treatments An Update on Osteoporosis Treatments Dr Mike Stone University Hospital Llandough Treatments for osteoporosis Calcium and vitamin D HRT Raloxifene Etidronate Alendronate Risedronate Ibandronate (oral and

More information

Osteoporosis Update. Case 2. Case 1: Monday morning, 8:15

Osteoporosis Update. Case 2. Case 1: Monday morning, 8:15 Osteoporosis Update Laura E. Ryan, MD Assistant Director for Special Programs Center for Women s Health Clinical Assistant Professor of Medicine Division of Endocrinology, Diabetes and Metabolism The Ohio

More information

Disclosures. Osteoporosis and Fracture Prevention. Objectives. Objectives. Osteoporosis Overview. Advisory Board: Hologic Advisory Board: LabCorp

Disclosures. Osteoporosis and Fracture Prevention. Objectives. Objectives. Osteoporosis Overview. Advisory Board: Hologic Advisory Board: LabCorp Disclosures Osteoporosis and Fracture Prevention Advisory Board: Hologic Advisory Board: LabCorp Nancy R. Berman MSN, ANP-BC, NCMP, FAANP Adult Nurse Practitioner/Colposcopist Certified Menopause Practitioner

More information

Forteo (teriparatide) Prior Authorization Program Summary

Forteo (teriparatide) Prior Authorization Program Summary Forteo (teriparatide) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1 FDA Indication 1 : Forteo (teriparatide) is indicated for: the treatment of postmenopausal women with osteoporosis

More information

Differentiating Pharmacological Therapies for Osteoporosis

Differentiating Pharmacological Therapies for Osteoporosis Differentiating Pharmacological Therapies for Osteoporosis Socrates E Papapoulos Department of Endocrinology & Metabolic Diseases Leiden University Medical Center The Netherlands Competing interests: consulting/speaking

More information

1

1 www.osteoporosis.ca 1 2 Overview of the Presentation Osteoporosis: An Overview Bone Basics Diagnosis of Osteoporosis Drug Therapies Risk Reduction Living with Osteoporosis 3 What is Osteoporosis? Osteoporosis:

More information

Page 1. Osteoporosis Warm-Up: Which of the Following is True? Diagnosis and Treatment of Osteoporosis: What is New in What s New in Osteoporosis

Page 1. Osteoporosis Warm-Up: Which of the Following is True? Diagnosis and Treatment of Osteoporosis: What is New in What s New in Osteoporosis Diagnosis and Treatment of Osteoporosis: What is New in 2017 Douglas C. Bauer, MD Professor of Medicine and Epidemiology & Biostatistics University of California, San Francisco No Disclosures Osteoporosis

More information

Page 1. Current and Emerging Strategies What s New in Osteoporosis. Osteoporosis. What is Osteoporosis? Traditional Risk Factors for Fracture

Page 1. Current and Emerging Strategies What s New in Osteoporosis. Osteoporosis. What is Osteoporosis? Traditional Risk Factors for Fracture Current and Emerging Strategies for Osteoporosis What s New in Osteoporosis Risk stratification Douglas C. Bauer, MD University of California, San Francisco Under recognition and poor compliance New potential

More information

Osteoporosis update. Dr. Claire Vandevelde Consultant Rheumatologist, LTHT

Osteoporosis update. Dr. Claire Vandevelde Consultant Rheumatologist, LTHT Osteoporosis update Dr. Claire Vandevelde Consultant Rheumatologist, LTHT Outline Background BMD Tools for assessing fracture risk Case study Denosumab Treatment breaks BMD BMD predicts fracture risk but

More information

OSTEOPOROSIS MEDICINES

OSTEOPOROSIS MEDICINES Bone Basics 2010. NOF. All rights reserved. National Osteoporosis Foundation 1150 17th Street, NW, Suite 850 Washington, DC 20036 (800) 223-9994 www.nof.org OSTEOPOROSIS MEDICINES Although there is no

More information

Screening Guidelines: Women

Screening Guidelines: Women The Situation 1 in 2 postmenopausal women and 1 in 5 older men will have an osteoporosis-related fracture in their lifetimes Osteoporosis Definition NIH Consensus Conference A skeletal disorder characterized

More information

Osteoporosis. Overview

Osteoporosis. Overview v2 Osteoporosis Overview Osteoporosis is defined as compromised bone strength that increases risk of fracture (NIH Consensus Conference, 2000). Bone strength is characterized by bone mineral density (BMD)

More information

Tymlos (abaloparatide)

Tymlos (abaloparatide) Tymlos (abaloparatide) Policy Number: 5.01.638 Last Review: 11/2018 Origination: 10/2017 Next Review: 11/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Tymlos

More information

Osteoporosis/Fracture Prevention Clinician Guide SEPTEMBER 2017

Osteoporosis/Fracture Prevention Clinician Guide SEPTEMBER 2017 Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Osteoporosis/Fracture Prevention Clinician Guide SEPTEMBER 2017 Introduction This Clinician Guide was developed to assist Primary Care physicians

More information

Osteoporosis challenges

Osteoporosis challenges Osteoporosis challenges Osteoporosis challenges Who should have a fracture risk assessment? Who to treat? Drugs, holidays and unusual adverse effects Fracture liaison service? The size of the problem 1

More information

Osteoporosis Update: Keys to Improving Diagnosis and Preventing Fractures

Osteoporosis Update: Keys to Improving Diagnosis and Preventing Fractures Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/spotlight-on/osteoporosis-update-keys-improving-diagnosis-preventingfractures/9812/

More information

Current and Emerging Approaches for Osteoporosis

Current and Emerging Approaches for Osteoporosis Current and Emerging Approaches for Osteoporosis Douglas C. Bauer, MD Professor of Medicine and Epidemiology & Biostatistics University of California, San Francisco No Disclosures What s New in Osteoporosis

More information

SpongeBone Menopants*

SpongeBone Menopants* SpongeBone Menopants* Adam Fershko, MD, FACP Kettering Health Network *Postmenopausal Osteoporosis Objectives O Epidemiology O Clinical significance O Pathophysiology O Screening and Diagnosis O Treatment

More information

Osteoporosis. Definition

Osteoporosis. Definition Osteoporosis Definition Osteoporosis causes bones to become weak and brittle so brittle that a fall or even mild stresses like bending over or coughing can cause a fracture. Osteoporosis-related fractures

More information

Emerging Challenges in Primary Care: Osteoporosis and Fracture Prevention Strategies

Emerging Challenges in Primary Care: Osteoporosis and Fracture Prevention Strategies Emerging Challenges in Primary Care: 2017 Osteoporosis and Fracture Prevention Strategies Faculty Nancy R. Berman, MSN, ANP-BC, NCMP, FAANP Adult Nurse Practitioner Certified Menopause Practitioner Millennium

More information

Emerging Challenges in Primary Care: Osteoporosis and Fracture Prevention Strategies. Faculty. Disclosures. [Insert Lecture Name Here]

Emerging Challenges in Primary Care: Osteoporosis and Fracture Prevention Strategies. Faculty. Disclosures. [Insert Lecture Name Here] Emerging Challenges in Primary Care: 2017 Osteoporosis and Fracture Prevention Strategies Faculty Nancy R. Berman, MSN, ANP-BC, NCMP, FAANP Adult Nurse Practitioner Certified Menopause Practitioner Millennium

More information

Researchers estimate that approximately 10.2 million

Researchers estimate that approximately 10.2 million Osteoporosis: A quick update This review of the latest recommendations regarding screening and Tx regimens can help you refine your approach and reduce patients risk of s. Lovedhi Aggarwal, MD; Camlyn

More information

Monitoring Osteoporosis Therapy

Monitoring Osteoporosis Therapy Monitoring Osteoporosis Therapy SUZANNE MORIN DEPT OF MEDICINE, DIVISION OF GENERAL INTERNAL MEDICINE, MUHC CENTRE FOR OUTCOMES RESEARCH AND EVALUATION, RI MUHC November 2017 Conflict of Interest Disclosures

More information

Treatment of Osteoporosis: IHFD 6 th March 2015

Treatment of Osteoporosis: IHFD 6 th March 2015 Treatment of Osteoporosis: IHFD 6 th March 2015 Dr. John J. Carey, MB, MS, FACR, FRCPI, CCD. Consultant Physician Galway University Hospitals Associate Professor in Medicine, NUIG, Galway Vice-President

More information

This Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only.

This Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only. This Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only. INJECTABLE OSTEOPOSIS AGENTS SUBJECT Pharmacologic Agents: Bisphosphonates: Boniva IV (ibandronate) Reclast (zoledronic

More information

Drug Intervals (Holidays) with Oral Bisphosphonates

Drug Intervals (Holidays) with Oral Bisphosphonates Drug Intervals (Holidays) with Oral Bisphosphonates Rizwan Rajak Consultant Rheumatologist & Lead for Osteoporosis GP Postgraduate Meeting April 2018 Contents Case presentation Pathway for Bisphosphonate

More information

AETNA BETTER HEALTH Prior Authorization guideline for Injectable Osteoporosis Agents

AETNA BETTER HEALTH Prior Authorization guideline for Injectable Osteoporosis Agents AETNA BETTER HEALTH Prior Authorization guideline for Injectable Osteoporosis Agents Injectable Osteoporosis Agents Forteo (teriparatide); zoledronic acid Prolia (denosumab)] Authorization guidelines For

More information

Name of Policy: Zoledronic Acid (Reclast ) Injection

Name of Policy: Zoledronic Acid (Reclast ) Injection Name of Policy: Zoledronic Acid (Reclast ) Injection Policy #: 355 Latest Review Date: May 2011 Category: Pharmacy Policy Grade: Active Policy but no longer scheduled for regular literature reviews and

More information

2016 AACE/ACE POSTMENOPAUSAL OSTEOPOROSIS GUIDELINES: Practical Applications. Outline. The Process. Osteoporosis Diagnosis NEW CLINICAL DEFINITION

2016 AACE/ACE POSTMENOPAUSAL OSTEOPOROSIS GUIDELINES: Practical Applications. Outline. The Process. Osteoporosis Diagnosis NEW CLINICAL DEFINITION 2016 AACE/ACE POSTMENOPAUSAL OSTEOPOROSIS GUIDELINES: Practical Applications Steven M. Petak MD, JD, MACE, FACP Associate Clinical Professor Weill-Cornell Medical College Division Head and Chief of Endocrinology

More information